Prevention and therapy of bronchopulmonary dysplasia - evidence and clinical practice.
- Author:
Wolfgang THOMAS
1
;
Christian P SPEER
Author Information
1. University Children's Hospital, University of Wurzburg, Germany. thomas_w@kinderklinik.uni-wuerzburg.de
- Publication Type:Journal Article
- MeSH:
Antioxidants;
therapeutic use;
Bronchopulmonary Dysplasia;
prevention & control;
therapy;
Caffeine;
therapeutic use;
Diuretics;
therapeutic use;
Erythromycin;
therapeutic use;
Humans;
Incidence;
Infant, Newborn;
Nitric Oxide;
administration & dosage;
Oxygen;
therapeutic use;
Ureaplasma urealyticum;
drug effects
- From:
Chinese Journal of Contemporary Pediatrics
2007;9(3):264-277
- CountryChina
- Language:Chinese
-
Abstract:
The knowledge on the pathogenetic mechanisms of bronchopulmonary dysplasia (BPD) has increased considerably over recent years. However, the incidence of the disease has not substantially been changed by our therapeutic approaches. This review summarizes the existing evidence for a number of respiratory and medical strategies to prevent or ameliorate the disease and gives recommendations for clinical practice. Oxygen plays an important pathogenetic and therapeutic role for BPD. Targeting infants at lower oxygen saturation levels than traditionally used seems to confer major advantages. There is no sufficient evidence for a routine use of respiratory strategies like permissive hypercapnia or inhaled nitric oxide to prevent BPD. Diuretics can ameliorate lung function transiently. High intramuscular doses of vitamin A can reduce the risk of BPD. Early or prophylactic surfactant might also be advantageous. Postnatal corticosteroids are effective but, due to their severe side effects, should be restricted to the severest cases. Alpha1-proteinase inhibitor and superoxide dismutase have no proven benefits for BPD. The role of erythromycin has not been completely elucidated yet. Innovative strategies like Clara Cell 10 kD protein still have to be assessed in future trials.
